Oca2 modulators, compositions and uses thereof
AssigneeAurora Pharmaceuticals Ltd
InventorRan GREENBERG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for modifying the eye color of a subject via modulation of the levels and/or activity and/or stability of the OCA2 protein. The present disclosure further relates to at least one OCA2 protein modulating agent or any compositions comprising the same and uses thereof.
Claims21
1-56. (canceled)
A method of modifying the eye color of a subject comprising administering to said subject an effective amount of at least one Oculocutaneous Albinism 2 (OCA2) protein modulating agent, or any vehicle, matrix, nano- or micro-particle thereof or any composition comprising the same.
A composition for modifying the eye color of a subject comprising at least one Oculocutaneous Albinism 2 (OCA2) protein modulating agent.
A pharmaceutical composition comprising at least one Oculocutaneous Albinism 2 (OCA2) protein modulating agent and at least one of pharmaceutically acceptable carrier/s, diluent/s and/or excipient/s.
A nucleic acid molecule for modifying the eye color of a subject comprising at least one Oculocutaneous Albinism 2 (OCA2) protein modulating agent.
A method of treating a disease/disorder in a subject in need thereof comprising administering to said subject an effective amount of at least one Oculocutaneous Albinism 2 (OCA2) protein modulating agent or any vehicle, matrix, nano- or micro-particle thereof or any composition comprising the same.
Dependencies are inferred from the claim text.